Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice

Forensic Toxicology

Volumn 34, Issue 2, 2016, Pages 329-343

  Hess, Cornelius ^a   Schoeder, Clara T ^b   Pillaiyar, Thanigaimalai ^b   Madea, Burkhard ^a   Müller, Christa E ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

GPR18; GPR55; Indazoles; Indoles; Structure activity relationship; Synthetic cannabinoid

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPR18 PROTEIN; GPR55 PROTEIN; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CAMP ASSAY; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; FORENSIC TOXICOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING ASSAY; SPICE; STRUCTURE ACTIVITY RELATION;

EID: 84969142647     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-016-0320-2     Document Type: Article

References (48)

1. Fredriksson R, Lagerstrom MC, Lundin L, Schioth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63:1256–1272
2. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161–202
3. Ashton CH (2001) Pharmacology and effects of cannabis: a brief review. Br J Psychiat 178:101–106
4. Mackie K (2006) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46:101–122
5. O’Keefe L, Simcocks AC, Hryciw DH, Mathai ML, McAinch AJ (2014) The cannabinoid receptor 1 and its role in influencing peripheral metabolism. Diabetes Obes Metab 16:294–304
6. Pacher P, Kunos G (2013) Modulating the endocannabinoid system in human health and disease–successes and failures. FEBS J 280:1918–1943
7. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563–583
8. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65
9. 2 receptors in the brain: role in central immune function. Br J Pharmacol 153:240–251
10. Pacher P, Mechoulam R (2011) Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50:193–211
11. 2. Pharmacol Rev 62:588–631
12. 2 receptors. Pharmacol Therapeut 74:129–180
13. 2 receptor agonists. Bioorg Med Chem 13:89–112
14. Lynch ME, Ware MA (2015) Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol 10:293–301
15. Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L, Beuerle T (2009) Spice: a never ending story? Forensic Sci Int 191:58–63
16. 1 cannabinoid receptor. Bioorg Med Chem 11:539–549
17. Makriyannis A, Deng H (2001) Cannabimetric indole derivatives. WO 01(28557):A1
18. Xie XQ, Eissenstat M, Makriyannis A (1995) Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids. Life Sci 56:1963–1970
19. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson N, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101
20. McHugh D (2012) GPR18 in microglia: implications for the CNS and endocannabinoid system signalling. Br J Pharmacol 167:1575–1582
21. 9-Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol 165:2414–2424
22. Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Sugiura T (2009) 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem 145:13–20
23. 1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. Exp Neurol 261:44–52
24. 2 receptors modulates signalling. Br J Pharmacol 171:5387–5406
25. 1 receptor antagonist from Auxarthron reticulatum. ACS Med Chem Lett 2:866–869
26. Behrenswerth A, Volz N, Torang J, Hinz S, Brase S, Müller CE (2009) Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem 17:2842–2851
27. Rempel V, Volz N, Glaser F, Nieger M, Brase S, Muller CE (2013) Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. J Med Chem 56:4798–4810
28. Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (2015) Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chem Neurosci 6:1445–1458
29. 2 cannabinoid receptor activity. J Med Chem 51:1904–1912
30. Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol 31:223–240
31. Fuchs A, Rempel V, Müller CE (2013) The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonists. PLoS ONE 8:e77739. doi:10.1371/journal.pone.0077739
32. 1 receptors. Neuropharmacology 95:479–491
33. Blaazer AR, Lange JHM, van der Neut MAW, Mulder A, den Boon FS, Werkman TR, Kruse CG, Wadman WJ (2011) Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity. Eur J Med Chem 46:5086–5098
34. Wiley JL, Marusich JA, Martin BR, Huffman JW (2012) 1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. Drug Alcohol Depend 123:148–153
35. The Senate of the United States (2011) An act to amend the Controlled Substances Act to place synthetic drugs in Schedule I. 08.12.2011
36. Banister SD, Stuart J, Conroy T, Longworth M, Manohar M, Beinat C, Wilkinson SM, Kevin RC, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (2015) Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicol 33:355–366
37. Louis A, Peterson BL, Couper FJ (2014) XLR-11 and UR-144 in Washington state and state of Alaska driving cases. J Anal Toxicol 38:563–568
38. Karinen R, Tuv SS, Oiestad EL, Vindenes V (2015) Concentrations of APINACA, 5F-APINACA, UR-144 and its degradant product in blood samples from six impaired drivers compared to previous reported concentrations of other synthetic cannabinoids. Forensic Sci Int 246:98–103
39. Wrobleski ST, Chen P, Hynes J Jr, Lin S, Norris DJ, Pandit CR, Spergel S, Wu H, Tokarski JS, Chen X, Gillooly KM, Kiener PA, McIntyre KW, Patil-Koota V, Shuster DJ, Turk LA, Yang G, Leftheris K (2003) Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J Med Chem 46:2110–2116
40. 2 cannabinoid receptor activity. J Med Chem 53:295–315
41. Behonick G, Shanks KG, Firchau DJ, Mathur G, Lynch CF, Nashelsky M, Jaskierny DJ, Meroueh C (2014) Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol 38:559–562
42. Schep LJ, Slaughter RJ, Hudson S, Place R, Watts M (2015) Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol 34:557–560
43. Rempel V, Volz N, Hinz S, Karcz T, Meliciani I, Nieger M, Wenzel W, Brase S, Müller CE (2012) 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists. J Med Chem 55:7967–7977
44. Rempel V, Atzler K, Behrenswerth A, Karcz T, Schoeder C, Hinz S, Kaleta M, Thimm D, Kiec-Kononowicz K, Müller CE (2014) Bicyclic imidazole-4-one derivatives: a new class of antagonists for the orphan G protein-coupled receptors GPR18 and GPR55. Med Chem Commun 5:632–649
45. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME (2009) Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284:29817–29827
46. Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, Brooker L, Goebel C, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (2013) The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem Neurosci 4:1081–1092
47. Rempel V, Volz N, Hinz S, Karcz T, Meliciani I, Nieger M, Wenzel W, Bräse S, Müller CE (2012) 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists. J Med Chem 55:7967–7977
48. 2 receptors and blockade of the related GPR55. ACS Med Chem Lett 4:41–45